Patient-Reported Outcomes and Health-Care Resource Utilization in Patients with Psoriasis Treated with Etanercept: Continuous versus Interrupted Treatment

Gelfand, Joel M.; Kimball, Alexa B.; Mostow, Eliot N.; Chiou, Chiun–Fang; Patel, Vaishali; Xia, H. Amy; Freundlich, Bruce; Stevens, Seth R.

doi:10.1111/j.1524-4733.2007.00251.x

Cited by 59 publications

(47 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Secondly, this population gave us the ideal opportunity to explore the effect of TNF antagonism on 5-HTT. Earlier research in this population has shown that TNF antagonism was associated with an antidepressant effect that was independent of disease improvement (Gelfand et al, 2008;Krishnan et al, 2007;Langley et al, 2010;Tyring et al, 2006). Consistent with previous studies, TNF-α explained only around 3% of and brain stem 5-HTT availability explained only around 7% variance in depression severity (Gryglewski et al, 2014;Valkanova et al, 2013).…”

Section: Discussionsupporting

confidence: 78%

Circulating tumour necrosis factor is highly correlated with brainstem serotonin transporter availability in humans

Krishnadas

Nicol

Sassarini

et al. 2016

Brain, Behavior, and Immunity

View full text Add to dashboard Cite

Circulating Tumour Necrosis Factor is highly correlated with brainstem serotonin transporter availability in humans, Brain, Behavior, and Immunity (2015), doi: http://dx.doi.org/ 10. 1016/j.bbi.2015.08.005 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Discussionsupporting

confidence: 78%

Circulating tumour necrosis factor is highly correlated with brainstem serotonin transporter availability in humans

Krishnadas

Nicol

Sassarini

et al. 2016

Brain, Behavior, and Immunity

View full text Add to dashboard Cite

show abstract

“…Etanercept reduced depression 29% in psoriasis patients with minimal depression [24]. Ustekinumab reduced depression 55%; 27% and 12% of patients reported depression before and after treatment, respectively [25].…”

Section: Impact Of Treating Psoriasis On Depressionmentioning

confidence: 95%

Impact and management of depression in psoriasis patients

Korman

Hill

Alikhan

et al. 2016

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

“…In a case series, etanercept monotherapy reduced depression as measured by the Hamilton Depression Rating Scale, but not according to the Beck Depression Inventory-II [40]. In the context of comorbid psoriasis and depression, etanercept reduced depression by 29% as measured by the Beck Depression Inventory, while adalimumab reduced depression by 18.5% as measured by the Zung Self-Rating Depression Scale [41,42]. These results suggest that depression is reduced by anti-TNF-a biologics; however, the variability in depression screening tools hinders comparison between different medications in this treatment class (Table 1).…”

Section: Biologic Use In Psoriasis: Effects On Depressionmentioning

confidence: 99%

Psoriasis, Depression, and Inflammatory Overlap: A Review

et al. 2017

View full text Add to dashboard Cite

Psoriasis has an enormous impact on patients' lives and is frequently associated with depression. Depression in psoriasis may be attributed, at least in part, to elevated proinflammatory cytokines rather than the psychosocial impact of psoriasis itself. Biologics that target inflammatory cytokines treat the clinical manifestations of psoriasis, but may also play a role in reducing associated depression. Multiple biologics have decreased symptoms of depression during clinical trials in psoriasis; however, these studies used a variety of depression screening tools, which limits comparison. Furthermore, it is difficult to distinguish whether improved depression is the result of the direct anti-inflammatory effect of the biologic, or the indirect effect of improved psoriasis leading to better psychological status. Future studies evaluating depression in patients with psoriasis could benefit from a standardized depression screening tool to mitigate discrepancies and facilitate comparison across treatment types. Here, we highlight the inflammatory overlap between psoriasis and depression by examining the pathophysiology of depression, and reviewing psoriasis clinical studies that assessed depression as an outcome measure.

show abstract

Patient-Reported Outcomes and Health-Care Resource Utilization in Patients with Psoriasis Treated with Etanercept: Continuous versus Interrupted Treatment

Abstract: Continuous etanercept treatment provided greater sustained improvements in PROs than interrupted therapy; however, interrupting etanercept therapy, if needed, has predictable and manageable effects.

Cited by 59 publications

References 21 publications

Circulating tumour necrosis factor is highly correlated with brainstem serotonin transporter availability in humans

Circulating tumour necrosis factor is highly correlated with brainstem serotonin transporter availability in humans

Impact and management of depression in psoriasis patients

Psoriasis, Depression, and Inflammatory Overlap: A Review

Contact Info

Product

Resources

About